

Annette Wundes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1741055/publications.pdf>

Version: 2024-02-01

15
papers

403
citations

1040056

9
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

579
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS). <i>JAMA Neurology</i> , 2015, 72, 159.	9.0	158
2	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. <i>CNS Drugs</i> , 2020, 34, 185-196.	5.9	80
3	Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1729-1739.	3.0	41
4	Contribution of intangible costs to the economic burden of multiple sclerosis. <i>Journal of Medical Economics</i> , 2010, 13, 626-632.	2.1	24
5	What Do Healthcare Providers Advise Women with Multiple Sclerosis Regarding Pregnancy?. <i>Multiple Sclerosis International</i> , 2014, 2014, 1-5.	0.8	18
6	Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1162-1169.	3.0	17
7	Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study. <i>Advances in Therapy</i> , 2022, 39, 1810-1831.	2.9	16
8	Improving the quality of depression and pain care in multiple sclerosis using collaborative care: The MS-care trial protocol. <i>Contemporary Clinical Trials</i> , 2018, 64, 219-229.	1.8	15
9	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642199399.	3.5	12
10	Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 " Fatigue (MS) 8a. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103117.	2.0	10
11	FDG-PET abnormalities leading to the diagnosis of an unusual case of probable neurosarcoidosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e506.	6.0	5
12	Brain pathology of a patient 7 years after autologous hematopoietic stem cell transplantation for multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2017, 373, 339-341.	0.6	3
13	Experiences and Perspectives of Pregnancy in Women with Multiple Sclerosis. <i>Sexuality and Disability</i> , 2015, 33, 47-52.	1.0	2
14	Accelerating international MS care through videoconference-based education and case consultation. <i>Neurology</i> , 2016, 87, e8-e10.	1.1	1
15	Encephalitis and Myelitis in a Young Woman. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1026.	6.0	1